Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), headquartered in Tarrytown, New York, is an integrated biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of medicines for the treatment of serious medical conditions, including eye disease, colorectal cancer, and rare inflammatory conditions.

Regeneron’s shares are predicted to rise tomorrow as the company received the FDA approval of EYLEA (aflibercept) injection for the treatment of diabetic macular edema (DME) – a common complication in the eyes of diabetic patients.

Source: Regeneron Pharmaceuticals Inc.

The approval was based on the one-year data Phase 3 VISTA_DME and VIVID-DME studies, which compared EYLEA 2 mg given monthly, EYLEA 2mg given every two months, or macular laser photocoagulation. The results, thus, showed statistically significant for the monthly and the every two months dosages. From both trials, patients on average gained the ability to read approximately two additional lines on the eye chart compared to no change in the control group.

As the diabetes mellitus market is growing at a rapid rate globally, Regeneron, alike Osiris Therapeutics (NASDAQ:OSIR), has the advantage and potentially shine with its new product once it is commercialized.

Shares of Regeneron are trading in a range of $301.68 to $307.66. The 52-week range of the stock is $227.64 to $352.49 PS. The company has a market cap of $30.72 billion with a P/E ratio of 88.01.

Read More at  Retail Investor 360